HSD11B2 | Hydroxysteroid (11-beta) dehydrogenase 2 | Disease related genes Predicted membrane proteins
| | | | | Tissue enhanced |
HTRA1 | HtrA serine peptidase 1 | Disease related genes Enzymes Plasma proteins Potential drug targets Predicted secreted proteins
| | | | | Tissue enhanced |
HTT | Huntingtin | Disease related genes Plasma proteins Predicted membrane proteins
| | | | | Expressed in all |
IL1RN | Interleukin 1 receptor antagonist | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
IL4R | Interleukin 4 receptor | Cancer-related genes CD markers Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
INS-IGF2 | INS-IGF2 readthrough | Predicted secreted proteins
| | | | | Tissue enriched |
IQGAP1 | IQ motif containing GTPase activating protein 1 | Plasma proteins
| | | | | Expressed in all |
ITPR1 | Inositol 1,4,5-trisphosphate receptor, type 1 | Disease related genes Plasma proteins Potential drug targets Predicted membrane proteins Transporters
| | | | | Expressed in all |
ITPR3 | Inositol 1,4,5-trisphosphate receptor, type 3 | Plasma proteins Predicted membrane proteins
| | | | | Mixed |
KANK1 | KN motif and ankyrin repeat domains 1 | Disease related genes Plasma proteins
| | | | | Expressed in all |
KAT2B | K(lysine) acetyltransferase 2B | Cancer-related genes Enzymes
| | | | | Expressed in all |
KCNA10 | Potassium voltage-gated channel, shaker-related subfamily, member 10 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Not detected |
KCNAB1 | Potassium voltage-gated channel, shaker-related subfamily, beta member 1 | Transporters
| | | | | Tissue enhanced |
KCNAB2 | Potassium voltage-gated channel, shaker-related subfamily, beta member 2 | Plasma proteins
| | | | | Expressed in all |
KCNC2 | Potassium voltage-gated channel, Shaw-related subfamily, member 2 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNE2 | Potassium voltage-gated channel, Isk-related family, member 2 | Disease related genes Predicted membrane proteins
| | | | | Tissue enriched |
KCNF1 | Potassium voltage-gated channel, subfamily F, member 1 | Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enriched |
KCNG1 | Potassium voltage-gated channel, subfamily G, member 1 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNH1 | Potassium voltage-gated channel, subfamily H (eag-related), member 1 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNQ1 | Potassium voltage-gated channel, KQT-like subfamily, member 1 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
LPIN2 | Lipin 2 | Disease related genes Enzymes Plasma proteins Potential drug targets
| | | | | Mixed |
LYN | V-yes-1 Yamaguchi sarcoma viral related oncogene homolog | Cancer-related genes Disease related genes Enzymes Potential drug targets
| | | | | Mixed |
MAP2K1 | Mitogen-activated protein kinase kinase 1 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets RAS pathway related proteins
| | | | | Expressed in all |
MAP2K2 | Mitogen-activated protein kinase kinase 2 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets RAS pathway related proteins
| | | | | Expressed in all |
MAP2K3 | Mitogen-activated protein kinase kinase 3 | Disease related genes Enzymes Potential drug targets
| | | | | Expressed in all |
MAPK1 | Mitogen-activated protein kinase 1 | Cancer-related genes Cytoskeleton related proteins Enzymes FDA approved drug targets Plasma proteins RAS pathway related proteins
| | | | | Expressed in all |
MAPK3 | Mitogen-activated protein kinase 3 | Cancer-related genes Cytoskeleton related proteins Enzymes FDA approved drug targets RAS pathway related proteins
| | | | | Expressed in all |
MARCKS | Myristoylated alanine-rich protein kinase C substrate | Plasma proteins
| | | | | Expressed in all |
MAX | MYC associated factor X | Cancer-related genes Transcription factors
| | | | | Expressed in all |
MCU | Mitochondrial calcium uniporter | Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
MZB1 | Marginal zone B and B1 cell-specific protein | Predicted secreted proteins
| | | | | Tissue enhanced |
NDUFAF2 | NADH dehydrogenase (ubiquinone) complex I, assembly factor 2 | Disease related genes Mitochondrial proteins
| | | | | Expressed in all |
NGFR | Nerve growth factor receptor | Cancer-related genes CD markers Predicted membrane proteins RAS pathway related proteins
| | | | | Mixed |
NKX6-1 | NK6 homeobox 1 | Transcription factors
| | | | | Tissue enhanced |
NPPA | Natriuretic peptide A | Candidate cardiovascular disease genes Disease related genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
OSBPL8 | Oxysterol binding protein-like 8 | Predicted membrane proteins
| | | | | Expressed in all |
OTC | Ornithine carbamoyltransferase | Disease related genes Enzymes Mitochondrial proteins Plasma proteins Potential drug targets
| | | | | Group enriched |
OXCT1 | 3-oxoacid CoA transferase 1 | Disease related genes Enzymes Mitochondrial proteins Potential drug targets Predicted secreted proteins
| | | | | Tissue enhanced |
PAK1 | P21 protein (Cdc42/Rac)-activated kinase 1 | Enzymes Plasma proteins RAS pathway related proteins
| | | | | Expressed in all |
PAPPA2 | Pappalysin 2 | Enzymes Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
PARP1 | Poly (ADP-ribose) polymerase 1 | Cancer-related genes Enzymes Plasma proteins
| | | | | Expressed in all |
PASK | PAS domain containing serine/threonine kinase | Enzymes
| | | | | Tissue enhanced |
PC | Pyruvate carboxylase | Citric acid cycle related proteins Disease related genes Enzymes Mitochondrial proteins Plasma proteins Potential drug targets
| | | | | Expressed in all |
PCK2 | Phosphoenolpyruvate carboxykinase 2 (mitochondrial) | Citric acid cycle related proteins Disease related genes Enzymes Mitochondrial proteins Plasma proteins Potential drug targets
| | | | | Group enriched |
PCSK2 | Proprotein convertase subtilisin/kexin type 2 | Enzymes Predicted secreted proteins
| | | | | Tissue enhanced |
PDE8B | Phosphodiesterase 8B | Disease related genes Enzymes FDA approved drug targets
| | | | | Tissue enriched |
PDGFB | Platelet-derived growth factor beta polypeptide | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Plasma proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Mixed |
PDK2 | Pyruvate dehydrogenase kinase, isozyme 2 | Enzymes Mitochondrial proteins
| | | | | Expressed in all |
PFKFB2 | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 | Enzymes
| | | | | Expressed in all |
PHPT1 | Phosphohistidine phosphatase 1 | | | | | | Expressed in all |